

Annual results

for the year ended 31 March 2013

Press conference 15 May 2013





Stefano Pessina Executive Chairman

Regulatory statement

Origination of information

Unless otherwise stated, the information contained in this presentation is derived from Alliance Boots own internal resources or research, or are the Company's estimates based on its existing knowledge and experience.

Forward-looking statements

Certain statements included in this presentation, or made in response to questions during Questions & Answers which are not historical facts, are forward-looking statements. These forward-looking statements involve certain risks and uncertainties including, but not limited to, changes in interest rates, competitive pressures, changes in customer mix, financial stability of major customers, investment procurement opportunities, acquisitions, industry consolidation, asserted and unasserted claims, and changes in government regulations or the interpretation thereof, which could cause actual results to differ from those in the forward-looking statements. The Company does not undertake to update any forward-looking statements to reflect events or circumstances after the date of this presentation, unless legally obligated to do so.

Confidentiality

This presentation and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.



Annual results 2012/13



"A transformational year for Alliance Boots"




Alliance Boots and Walgreens form strategic partnership





Joint agreement with AmerisourceBergen







2012/13 highlights



"Alliance Boots has again delivered double digit growth in underlying profit after tax...

...while at the same time generating a strong cash flow"



Health & Beauty Division







Pharmaceutical Wholesale Division








Delivering higher profits year after year



Underlying profit (after tax) £million





Prior year figures have been re-stated for the adoption of the revised IAS19 Employee Benefits standard





George Fairweather Group Finance Director

Group financial highlights

Year ended 31 March 2013

Revenue: c.£22.4bn

- down 2.6% (up 0.6% constant currency)

Trading profit: £1,265m - up 6.1% (up 7.4% constant currency)

Underlying profit (after tax): £805m - up 12.7%

Statutory profit: £741m - up 25.0%



Group financial highlights

Year ended 31 March 2013

Cash generated from operations: £1,648m

Net borrowings reduction: £1,124m - to c.£5.9bn



Health & Beauty Division



Year ended 31 March 2013

Revenue: c.£7.5bn

- down 2.5% (down 2.1% constant currency)

Trading margin: 11.6% - up 1.0pp

Trading profit: £865m

- up 6.8% (up 7.0% constant currency)



Year ended 31 March 2013

Health & Beauty – UK

Revenue: c.£6.5bn - down 2.4%

Trading margin: 12.4% - up 1.3pp

Trading profit: £813m - up 8.8%

Comprises Boots UK and Boots Opticians















Boots UK - Dispensing



Year ended 31 March 2013



Items dispensed: 222m - down 0.8% like for like





Boots UK - Retail

Year ended 31 March 2013

Total retail revenue: up 0.3%

Retail Health: up 1.3%

Beauty & Toiletries: up 1.2%

Boots Advantage Card: 17.9m active members





Optical / hearingcare

Year ended 31 March 2013

Boots Opticians

- like for like revenue up 2.7%
- higher spectacle sales

Boots hearingcare

- partnership with Sonova









Health & Beauty - International




Year ended 31 March 2013

Revenue: £935m

down 3.1%
(-0.1% constant currency)

Trading profit: £52m down 17.5% (-14.3% constant currency)

Revenue mix by country



Net 26 stores added during year



Health & Beauty - International

Year ended 31 March 2013

Product sales to US retailers - up c.12%

No7 launched in Walgreens

- new Hollywood store

Dairy Farm trial

- in select Mannings health and beauty stores in Hong Kong









Pharmaceutical markets







Pharmaceutical Wholesale Division



Year ended 31 March 2013

Revenue: £16.4bn

- down 2.7% (up 1.5% constant currency)

Trading margin: 2.7% - up 0.2pp

Trading profit: £435m - up 5.1% (up 8.2% constant currency)



Pharmaceutical Wholesale Division







Alliance





Intelligente Lösungen für Ihren Erfolg





Associates and joint ventures

Year ended 31 March 2013

Share of underlying post tax earnings: £39m

Alliance Healthcare Russia

- acquired in November 2012

Guangzhou Pharmaceuticals Corp.

- performed well

Nanjing Pharmaceutical

- intention to acquire 12% equity interest














Programme progressing well

Walgreens Boots Alliance Development JV

- established in Switzerland

Synergies in line with expectations

- our share: c.£14m pre tax (net of direct costs)



Net finance costs and tax

Year ended 31 March 2013

Underlying net finance costs: £320m - down £64m

Underlying tax charge: £179m

Tax paid: £114m

- up £31m
 - up £38m in UK



Prior year figures have been re-stated for the adoption of the revised IAS19 Employee Benefits standard

Cash flow and balance sheet

Year ended 31 March 2013

Cash generated from operations: £1,648m

Cash capital expenditure: £200m

Acquisition related expenditure: £84m



Net borrowings and equity

Year ended 31 March 2013

Net borrowings reduced by £1,124m - to c.£5.9bn

Existing borrowing facilities extended - c.£5.2bn extended by 2-3 years

Facility amendments

- to facilitate full combination with Walgreens

Equity: £5.7bn



Financial outlook





Alliance Boots



Alex Gourlay

Chief Executive, Health & Beauty Division

Increasing our range of healthcare services













Developing our multi-channel offer









Launching innovative new products





Launching innovative new products





Launching innovative new products







Launching innovative new products







Launching innovative new products








Increasing sales of Boots product brands across the world








Alliance Boots



Ornella Barra Chief Executive, Pharmaceutical Wholesale Division



Our unparalleled scale and market presence



Wholesale operations in 20 countries^{*}



Owned businesses Associates & joint ventures

* including associates & joint ventures

Further developing our new business model



Further developing our new business model











Developing our offering for manufacturers





Improving the health and wellbeing of the communities we serve











Walgreens AmerisourceBergen®





Partnering with pharmaceutical manufacturers across the globe





Internationalising our unique product brands





Building our network in geographies with long-term growth potential





We have the vision... creativity... and management expertise...



Annual results 2012/13



"A transformational year for Alliance Boots"



Alliance Boots GmbH Copyright and trade mark notices All rights reserved © Copyright 2013 Alliance UniChem IP Limited

BOOTS, BOOTS ADVANTAGE CARD, BOOTS HEARINGCARE, BOOTS OPTICIANS, BOOTS PHARMACEUTICALS, BOOTS UK, BOOTS.COM, BOOTSWEBMD.COM, BOTANICS, NO7, NO7 FOUNDATION MATCH MADE SERVICE and SEVENTEEN are trade marks owned by The Boots Company PLC.

ALCURA, ALLIANCE HEALTHCARE, ALLIANCE HEALTHCARE DEUTSCHLAND, ALLIANCE HEALTHCARE RUSSIA, ALLOGA, ALMUS, ALVITA and SKILLS IN HEALTHCARE are trade marks owned by Alliance Unichem IP Limited.

ALPHEGA FARMACIA and ALPHEGA PHARMACY are trade marks owned by Alliance Healthcare France Société Anonyme.

ANZAG is a trade mark owned by Alliance Healthcare Deutschland.

